Brooke D. Paradise

TL;DR: The Hh/GLI pathway was originally discovered in Drosophila as a major regulator of segment patterning in development as mentioned in this paper, and it is observed in many types of cancer including basal cell carcinoma, medulloblastoma, colorectal, prostate, pancreatic, and many more.

TL;DR: Pre-clinical evidence supporting the suitability of targeting this signaling pathway in cancers is summarized, and published and ongoing clinical trial data on single agent or combination therapeutic strategies, targeting Hedgehog/GLI signaling pathway, in both advanced solid tumors and hematologic malignancies are provided.

TL;DR: A mechanism regulated by the oncogenic SOX2-GLI1 transcriptional complex driving melanoma invasion through the induction of the sialyltransferase ST3GAL1 is reported, supporting a key role of the ST3 GAL1-AXL axis as driver of melanoma metastasis and highlighting the therapeutic potential of targeting this axis to treat metastatic melanoma.

TL;DR: The potential to “reprogram” cancer cells to revert them to a healthy state presents great promise and merits further investigation.

TL;DR: In this paper, a novel SOX2-BRD4-GLI1 complex was identified to drive the expression of GLI1, the final effector of the hedgehog/GLI pathway, providing a novel mechanism of non-canonical SMO-independent activation of HH and GLI signaling in melanoma.